Stoke Therapeutics at 36th International Epilepsy Congress

P358: EMPEROR Phase 3 study design:

Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome

P351: Substantial improvements in overall seizure burden and seizure-free days in patients with Dravet syndrome treated with zorevunersen:

Results from Phase 1/2a and open-label extension studies

Oral presentation

Zorevunersen demonstrates potential as a disease‑modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 36 months of maintenance dosing in open-label extension studies